Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALUR 
Allurion Technologies, Inc. (ALUR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: ALUR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $8.38
1 Year Target Price $8.38
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -55.1% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 17.00M USD | Price to earnings Ratio - | 1Y Target Price 8.38 |
Price to earnings Ratio - | 1Y Target Price 8.38 | ||
Volume (30-day avg) 4 | Beta -0.5 | 52 Weeks Range 1.98 - 20.00 | Updated Date 09/16/2025 |
52 Weeks Range 1.98 - 20.00 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -10.13 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date 2025-08-19 | When - | Estimate -0.13 | Actual -1.28 |
Profitability
Profit Margin -153.93% | Operating Margin (TTM) -205.74% |
Management Effectiveness
Return on Assets (TTM) -64.74% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 1.05 | Enterprise Value 34570390 | Price to Sales(TTM) 0.85 |
Enterprise Value 34570390 | Price to Sales(TTM) 0.85 | ||
Enterprise Value to Revenue 1.74 | Enterprise Value to EBITDA -2.15 | Shares Outstanding 7762680 | Shares Floating 3985128 |
Shares Outstanding 7762680 | Shares Floating 3985128 | ||
Percent Insiders 10.26 | Percent Institutions 40.98 |
Upturn AI SWOT
Allurion Technologies, Inc.
Company Overview
History and Background
Allurion Technologies, Inc. focuses on developing innovative solutions for weight loss. Founded in 2009, it gained recognition for its Elipse balloon, a swallowable, procedure-less gastric balloon. The company has evolved to offer a comprehensive weight management program.
Core Business Areas
- Allurion Program: A weight-loss program centered around the Allurion Balloon, coupled with nutritional support and a connected scale and health tracker.
- Digital Health Tools: Includes the Allurion app and connected scale, providing data tracking and support for users and healthcare providers.
Leadership and Structure
The leadership team consists of executives with experience in medical devices and weight management. The organizational structure is focused on R&D, commercial operations, and global expansion.
Top Products and Market Share
Key Offerings
- Allurion Balloon: A swallowable, procedure-less gastric balloon designed to promote weight loss. Market share data is emerging and competitive. Competitors include Apollo Endosurgery (OTCQB:APEN) and other weight loss solutions providers. Specific Revenue numbers will be in the financial metrics section.
- Allurion Program: This program integrates the Allurion Balloon with nutritional support and a connected scale and health tracker. Revenue is tied to the Allurion Balloon program. This is a key differentiator. Competitors include traditional diet programs, surgery, and pharmaceutical interventions. Specific Revenue numbers will be in the financial metrics section.
Market Dynamics
Industry Overview
The weight loss market is large and growing, driven by rising obesity rates and increasing awareness of the health risks associated with excess weight. Demand is fueled by lifestyle changes and the desire for non-surgical options.
Positioning
Allurion Technologies, Inc. is positioned as an innovator in the non-surgical weight loss market, offering a unique, patient-friendly approach. Its competitive advantage lies in its swallowable balloon and integrated digital health platform.
Total Addressable Market (TAM)
The global weight management market is projected to reach hundreds of billions of dollars. Allurion is positioned to address a significant portion of this market through its non-surgical and digitally-enabled approach.
Upturn SWOT Analysis
Strengths
- Innovative product (swallowable balloon)
- Procedure-less placement
- Integrated digital health platform
- Global presence
- Strong brand recognition in specific markets
Weaknesses
- Relatively new to the public market
- Dependence on a single core product
- Need for continued clinical data to support efficacy
- Pricing may be a barrier for some patients
Opportunities
- Expansion into new geographic markets
- Development of new products and services
- Partnerships with healthcare providers
- Increased adoption of telehealth for weight management
Threats
- Competition from established weight loss companies
- Regulatory changes
- Negative publicity or safety concerns
- Economic downturn impacting consumer spending
Competitors and Market Share
Key Competitors
- APEN
- VTVT
- CRMD
Competitive Landscape
Allurion has a unique advantage with its swallowable balloon. However, it competes with established weight loss companies offering various solutions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by the adoption of the Allurion Balloon and expansion into new markets.
Future Projections: Analysts expect continued revenue growth, but profitability is uncertain. Projections depend on successful product development and market penetration.
Recent Initiatives: Recent initiatives include expanding the Allurion Program, launching new digital health tools, and securing regulatory approvals in key markets.
Summary
Allurion Technologies is an innovative player in the non-surgical weight loss market with a promising technology. Revenue growth is positive, but profitability remains a challenge. Continued investment in R&D, market expansion, and cost management are crucial for long-term success. They should continue to focus on differentiating themselves in a competitive market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate and subject to change. Investment decisions should be based on individual due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Allurion Technologies, Inc.
Exchange NYSE | Headquaters Natick, MA, United States | ||
IPO Launch date 2023-08-02 | Co-Founder, CEO, President, Principal Financial & Accounting Officer and Director Dr. Shantanu K. Gaur M.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 134 | Website https://www.allurion.com |
Full time employees 134 | Website https://www.allurion.com | ||
Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform offers the Allurion Program, a swallowable and procedure-less intragastric balloon for weight loss, as well as provides access to artificial intelligence-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. The company operates in Spain, France, Turkey, and internationally. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.